Temporal arthritis. Significant vascular FDG involvement was detected (77.7%) in these patients. 4 of 7 patients diagnosed Takayasu arthritis were not seen as histological finding in the other imaging modalities. Vascular FDG uptake (p < 0.001) was statistically significantly higher in the patients diagnosed with rheumatic disease whereas lymph node (p = 0.013) and bone (p = 0.005) FDG uptake were significantly higher in patients with malignancy. Patients with malignancy had the highest SUVmax mean value (p < 0.001).

Conclusion: Our findings reveal that PET-CT is a useful imaging modality in the FUO/IJO patients. Inflammatory diseases, especially large vessel vasculitis, should be considered in addition to malignancies in these patients, and subclinical inflammation in the blood vessel can be visualised by PET-CT.

Disclosure of Interests: None declared


AB1191 DIFFERENTIAL DIAGNOSIS OF SERONEGATIVE ARTHRITIS: DIAGNOSIS ONE YEAR FOLLOW UP AFTER FIRST DIAGNOSIS

Joo Guan Yeo1,2, Lu Pan1, Martin Wasser1, Pavanish Kumar1,
Thaschawee Arkachaisri2, Su Li Poh1, Fauzialia Ally1, Jing Yao Leong1, Kee Thai Yeo1,2, Liyun Lai1, Angela Yun June Tan2
Translational Immunology Institute, SingHealth/Duke-NUS Academic Medical Centre, Singapore, Singapore; 1KoCo Women’s and Children’s Hospital, Singapore, Singapore; 2Duke-NUS Medical School, Singapore, Singapore

Background: An atlas of the developing immune system will not only improve our understanding of normal immune ontogenesis but more importantly, aid in our identification of disease-associated cell subsets. However, such a resource is still unavailable despite accessibility to technologies like mass cytometry due to the general focus on specific cell subsets or ages. There is a critical unmet need for standardized datasets depicting at single cell level and with high dimensionality the entire developmental gradient of the healthy immune system from the neonatal to adult age.

Objectives: We aim to provide a detailed depiction of the architecture of the human healthy Immunome across an entire age gradient.

Methods: We have created a high dimensional atlas of the healthy human immunome (EPIC: Extended Poly-dimensional Immunome Characterization) by interrogating the peripheral blood mononuclear cells (PBMC) of over 200 healthy subjects, ranging from cord blood to adult age, with 63 unique mechanistic and phenotypic markers per cell by mass cytometry (CyTOF). The EPIC analytical and visualization pipeline is based on an open source web-based R Shiny bioinformatics toolkit that allows it to be easily accessible to the research community.

Results: EPIC can be mined in various ways, for instance to follow developmental changes of any given cell subset or to depict the architecture of the Immunome at any given age range. For example, transition developmental milestones were observed in the TNF+ CD4+ T cells where the size of its memory subset would exceed its naive subset at 8 year old. There was a significant reduction and increase in the frequency of the naive and memory TNF+ CD4+ T cells with a Spearman’s correlation coefficient, rho, of -0.4662 and 0.4164 respectively. More importantly, we have built and will keep developing datasets from various immune mediated diseases using the same approach. Consequently, by providing the healthy standard, EPIC enables the depiction and dissection of disease-dependent perturbations of the Immunome architecture.

Conclusion: EPIC provides a transformational conceptual advance in Translational Immunology from individual subset focused to immune architecture based approach for the understating of physiology and pathogenesis of immune mediated mechanisms. We intend to make EPIC available to the entire community in its full capacity.

REFERENCES
None

Disclosure of Interests: Joo Guan Yeo: None declared, Lu Pan: None declared Our findings were not seen in any other publication None declared, Pavanish Kumar: None declared, Thaschawee Arkachaisir: Speakers bureau; Abbvie Pte, Ltd, Su Li Poh: None declared, Fauzialia Ally: None declared, Jing yao Leong: None declared, Kee Thai Yeo: None declared, Liyun Lai: None declared, Angela Yun June Tan: None declared, Salvatore Albanii: None declared


AB1190 EXTENDED POLY-DIMENSIONAL IMMUNOME CHARACTERIZATION (EPIC): A WEB-BASED IMMUNE REFERENCE ATLAS OF THE HEALTHY HUMAN IMMUNOME AND A TOOL FOR TRANSLATIONAL MEDICINE

Joo Guan Yeo1,2, Lu Pan1, Martin Wasser1, Pavanish Kumar1,
Thaschawee Arkachaisri2, Su Li Poh1, Fauzialia Ally1, Jing Yao Leong1, Kee Thai Yeo1,2, Liyun Lai1, Angela Yun June Tan2
Translational Immunology Institute, SingHealth/Duke-NUS Academic Medical Centre, Singapore, Singapore; 1KoCo Women’s and Children’s Hospital, Singapore, Singapore; 2Duke-NUS Medical School, Singapore, Singapore

Objectives: To compare diagnosis of seronegative arthritis between initial and delayed diagnosis after one year follow up.

Methods: Arthritis patient who are sustained for more than one year since first refer despite his/her ACFA or Rheumatoid Factor were negative, were collected. From these patients, difference from initial diagnosis to second after one year follow up was evaluated statistically with chi square test. Mean EACC score and mean involved joint count for large and small joint (LJC and SJJC) at initial diagnosis were compared with each of second diagnosis statistically with Mann Whitney U test (MWU). Clinical course evaluated with 28-joints disease activity score (DAS28) and Health Assessment Questionnaire Disability Index (HAQ-DI) for each diagnosis was compared at every other 3 months with MWU. Comparison between 475 seropositive RA patients treated in the same institute and seronegative RA in the study was also evaluated in a same manner. These patients’ sensitivity and specificity (Sens & Specs) in according with 1987 ACR diagnosis criteria (1987ACR) was also evaluated and compared with Sens & Specs of AECC.

Results: Ninety-six patients were enrolled. In these, RA was diagnosed to 18 patients and 78 were unclassified arthritis as first diagnosis. Second diagnosis of these patients were RA for 41, spondyloarthropiths (SpA) for 22, collagen disease (CD) for 5, osteoarthritis (OA) for 9, hypothyroidism (HTh) for 2, non-tuberculous mycobacterium (NTM) for 1, and unclassified arthritis (UA) for 16. Mean EACC score and range for each second diagnosis was 5.2 and 2 to 7, 4.4 and 3 to 7, 4.4 and 3 to 5, 5.0 and 4 to 6, 4.0 and 4.0, and 4.25 and 3 to 5, for RA, SpA, CD, OA, HTh, NTM, and UA, respectively. There is no significant difference between any pair of second diagnoses. LJC and SJJC of each second diagnosis was 3.2 and 9.8, 5.7 and 4.8, 2.4 and 4.8, 2.4 and 8.1, 2.0 and 6, 2 and 2, and 1.8 and 5.9, for RA, SpA, CD, OA, HTh, NTM, and UA, respectively. There is also no significant difference between any pair of second diagnoses (Table). In clinical course, there is no significant difference between the second diagnoses, and also no significant difference between seropositive and seronegative RA.

In these seronegative arthritis patients, Sens & Specs of RA in accordance with 1987ACR were 75.0% and 43.4%, while 83.3% and 66.7% in seronegative RA.

Conclusion: Diagnosis of seronegative arthritis is not uncomplicated, whereas rheumatologist’s diagnostic skill is questioned.

Table: Comparison between second diagnosis

<table>
<thead>
<tr>
<th>Second diagnosis</th>
<th>First diagnosis</th>
<th>N</th>
<th>AECC</th>
<th>Joint point</th>
<th>LJC</th>
<th>SJJC</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>RA(15), UA(26)</td>
<td>41</td>
<td>5.2</td>
<td>3.7</td>
<td>3.2</td>
<td>9.8</td>
</tr>
<tr>
<td>SpA</td>
<td>RA(1), UA(21)</td>
<td>22</td>
<td>4.4</td>
<td>3.0</td>
<td>1.9</td>
<td>5.7</td>
</tr>
<tr>
<td>CD</td>
<td>UA(5)</td>
<td>5</td>
<td>4.4</td>
<td>2.8</td>
<td>2.4</td>
<td>4.8</td>
</tr>
<tr>
<td>OA</td>
<td>RA(2) or OA(7)</td>
<td>9</td>
<td>5.0</td>
<td>3.4</td>
<td>2.4</td>
<td>8.1</td>
</tr>
<tr>
<td>HTh</td>
<td>UA(2)</td>
<td>2</td>
<td>4.0</td>
<td>3.0</td>
<td>2.0</td>
<td>6.0</td>
</tr>
<tr>
<td>NTM</td>
<td>UA(1)</td>
<td>1</td>
<td>4.0</td>
<td>3.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>UA</td>
<td>UA(16)</td>
<td>16</td>
<td>4.25</td>
<td>3.0</td>
<td>1.8</td>
<td>5.9</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared